Vitestro raises €12m in Series A financing

With assets of €12m through a Series A financing, Dutch Vitestro NV aims to bring the world’s first autonomous blood drawing device to the market.

Read more

European VCs join US$105m financing of US Mediar Thx

Mediar Therapeutics (Cambridge, MA, USA), a company developing a portfolio of first-in-class therapies to treat fibrosis, announces a US$105m financing including a US$85m Series A co-led by Novartis Venture Fund and Sofinnova Partners (France). The round is further joined by Pfizer Ventures, Mission BioCapital, Bristol-Myers Squibb, Eli Lilly, Ono Venture Investment, Mass General Brigham Ventures but also from more European VCs like by Gimv together with Pureos.

Read more

Iktos SA raises €15.5m in Series A financing

Paris-based AI-inspired drug discovery specialist Iktos SA has closed a €15.5m financing to expand its  platform and kick-start the new CRO Iktos Robotics.

 

Read more

Oculis lists at Nasdaq through SPAC merger

The eye disease specialist Oculis Holding AG has been listed on Nasdaq following the merger of Oculis SA with European Biotech Acquisition Corp.

Read more

Confo Therapeutics and Lilly partner to advance CFTX-1554

Drug developer Confo Therapeutics and Eli Lilly & Company have inked a worldwide licensing agreement to co develop Confo’s neurophatic pain candidate CFTX-1554.

Read more

German HTGF IV fund closes at €493m

The fourth fund of High-Tech Gründerfonds has reached a final fund volume of €493.8m

Read more

5 Alarm Bio Ltd raises £500K in seed round

British anti-aging therapeutics developer 5 Alarm Bio Ltd has raised £500K in a seed financing for testing its lead compound FAB001 for healing chronic wounds.

Read more

High blood pressure reprograms immune system

Interferon-gamma overexpression leads to hypertension-induced damage to the blood-brain barrier by reprogrammed macrophages.

Read more

Abivax SA raises €130m to advance obefazimod to Phase III

French Abivax SA has raised €130m capital led by TCGX to accelerate Phase III testing of its ulcerative colitis candidate obefazimod extend its cashflow.

Read more

PVH Corp joins fiber-to-fiber consortium

PVH Corp has joined fiber-to-fiber consortium that wants to make textile recycling sustainable by establishing standards for biorecycled textile fibre.

Read more